About US
Contact us
-
GE Healthcare and Valneva collaboration results in cell culture medium for vaccine productionGE Healthcare’s Life Sciences business and integrated vaccine biotech company Valneva SE have successfully collaborated to optimise virus productivity in Valneva’s EB66 cell-line, a proprietary techno2016/11/7
-
Lonza opens drug product services laboratory in SwitzerlandChemicals and biotechnology company Lonza has opened its pharmaceutical Drug Product Services laboratory in the Stücki Science Park Basel (CH), Switzerland. The new 1,300m2facility will initially car2016/11/7
-
M&As this week: Canopy Growth Corporation, Novogen, Karo PharmaCanadian cannabis companyCanopy Growth Corporationhas completed the acquisition of medical cannabis company Vert Medical. The purchase consideration for the acquisition includes repayment of the targ2016/11/4
-
Merck and American Cancer Society release report on cancer death in womenMerck and the American Cancer Society (ACS) have released a report on causes of cancer-related mortality in women. Titled 'The Global Burden of Cancer in Women', the report is a result of the partner2016/11/4
-
UK team of health experts deployed to help control global disease outbreaksA UK team of health experts comprising clinicians, scientists and academicians will be deployed to respond to requests from countries worldwide to help control disease outbreaks within 48 hours. Know2016/11/3
-
Valeant reportedly holding talks to divest gastrointestinal treatment specialist businessValeant Pharmaceuticals is reportedly holding advanced talks to divest its gastrointestinal treatment specialist business to Japanese firm Takeda Pharmaceutical for approximately $10bn. According to2016/11/3
-
Medivir to sell BioPhausia to Karo PharmaMedivir has entered into an agreement to sell its subsidiary BioPhausia (Nordic Brands) to Karo Pharma forSkr908m ($100.9m). This price will be on a cash and debt free basis, including a normalised w2016/11/2
-
Astellas to acquire German company Ganymed Pharmaceuticals for €1.2bnJapan’s Astellas Pharma has signed an agreement to acquire German-based biopharmaceutical company Ganymed Pharmaceuticals for €1.2bn. With this transaction, Astellas will be able to continue to build2016/11/2
-
EMA validates MAA for avelumab for treatment of metastatic merkel cell carcinomaThe European Medicines Agency (EMA) has validated for review Merck KGaA's marketing authorisation application (MAA) for avelumab, for the proposed indication of metastatic merkel cell carcinoma (MCC).2016/11/1
-
Novartis LEE011 receives FDA Priority Review for first-line treatment of HR+ / HER2- advanced breast cancerThe US Food and Drug Administration (FDA) has accepted Novartis' New Drug Application (NDA) for filing and granted Priority Review for LEE011 (ribociclib) as first-line treatment of postmenopausal wom2016/11/1